Cytokinetics, Incorporated (Nasdaq: CYTK) has presented a broad package of new clinical data for MYQORZO at the European Society of Cardiology Heart Failure 2026 Congress.
The presentations reinforced the clinical profile of MYQORZO, known generically as aficamten, across multiple patient populations and treatment settings studied in ongoing trials.
Data came from three separate studies, including SEQUOIA-HCM, MAPLE-HCM, and FOREST-HCM, each examining different dimensions of aficamten’s performance in patients with obstructive hypertrophic cardiomyopathy.
SEQUOIA-HCM served as the pivotal Phase 3 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy, providing the foundational evidence base for the drug’s regulatory approvals.
MAPLE-HCM is a Phase 3 trial that directly compared aficamten to metoprolol, a widely used beta blocker, in patients with symptomatic obstructive hypertrophic cardiomyopathy.
FOREST-HCM is an open-label extension trial designed to assess the longer-term safety and durability of aficamten treatment across a range of patient demographics and clinical subgroups.
Cytokinetics delivered nine presentations in total at ESC Heart Failure 2026, with eight of those focused specifically on obstructive hypertrophic cardiomyopathy and its treatment with cardiac myosin inhibition.
A secondary analysis of sex differences from MAPLE-HCM showed that MYQORZO delivered consistent benefits in women despite entering the trial with more severe baseline characteristics than their male counterparts.
Women made up 42% of participants in MAPLE-HCM and experienced nearly identical improvements in peak oxygen consumption compared to men, with both groups gaining approximately 2.2 mL/kg/min in pVO2.
Both male and female patients recorded significant gains in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score alongside meaningful reductions in cardiac biomarkers and NT-proBNP levels.
A prospective analysis drawn from 122 patients in FOREST-HCM with interpretable ambulatory ECG data at screening assessed the arrhythmia risk associated with long-term aficamten treatment.
Findings showed that treatment with MYQORZO for up to 96 weeks did not increase the incidence of arrhythmias, including in patients who had withdrawn from beta-blocker therapy during the study period.
MYQORZO is a cardiac myosin inhibitor currently approved in the United States, Europe, and China for adults with symptomatic obstructive hypertrophic cardiomyopathy, representing a significant commercial footprint for Cytokinetics.
The collective body of evidence presented at ESC Heart Failure 2026 is intended to expand the clinical and real-world understanding of both MYQORZO and omecamtiv mecarbil across patient populations.
Cytokinetics continues to build its evidence base as it seeks to deepen the market position of MYQORZO across geographies where the drug has already secured regulatory approval.